ArticleBMC oral health2025
Photobiomodulation-pretreated dental follicle stem cells with enhanced osteogenic function improve alveolar bone regeneration.
Article in BMC oral health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundDental follicle stem cell (DFSC) therapy is an excellent option for reducing alveolar bone loss. Preconditioning DFSCs increases their resistance to the disease microenvironment and increases their efficacy. Photobiomodulation therapy (PBMT) is an effective and convenient way to precondition DFSCs. In this study, we evaluated the effects of PBMT-pretreated DFSCs on alveolar bone regeneration and investigated the underlying mechanism.
methodsAfter DFSCs were isolated and characterized, various biological properties of DFSCs following treatment with PBMT were evaluated in viability tests, wound healing assays, alizarin red staining, alkaline phosphatase staining, real-time quantitative PCR, mitochondrial membrane potential assays, and ATP and reactive oxygen species (ROS) measurements. Twenty-four 7-week-old SD rats were used to establish a periodontal defect model and were then divided into 3 groups: the control group, the DFSC group, and the PBMT + DFSC group. Microcomputed tomography and histological examination were conducted at two and four weeks.
resultsIn the in vitro study, the PBMT group showed better osteogenic capability than the control group. The gene expression levels of COL-1α, OCN, and RUNX2 in the PBMT group increased. Moreover, ROS and ATP levels and the mitochondrial membrane potential were greater in the PBMT group than in the other groups. In the in vivo study, the bone volume per total volume (BV/TV) in the PBMT + DFSC group was greater than those in the control and PBMT groups at four weeks. There was more new bone tissue, more trabeculae and higher expression of OCN and COL-I in the slices of the PBMT + DFSC group than in those of the other groups.
conclusionsPBMT facilitated bone regeneration in periodontal defect models by enhancing the osteogenic and mitochondrial functions of DFSCs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.